Home Neuronal Signaling 5-HT Receptor agonist - Dopamine Receptor antagonist Quetiapine

research use only

Quetiapine 5-HT Receptor agonist

Cat.No.S5741

Quetiapine(ICI204636) is an atypical antipsychotic used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. This compound is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. It is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. This chemical has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.23, 5.74, 7.54, 5.55.
Quetiapine 5-HT Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 383.51

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S574101 DMSO]77 mg/mL]false]]]false]]]false Purity: 99.96%
99.96

Chemical Information, Storage & Stability

Molecular Weight 383.51 Formula

C21H25N3O2S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 111974-69-7 -- Storage of Stock Solutions

Synonyms ICI204636 Smiles C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42

Solubility

In vitro
Batch:

DMSO : 77 mg/mL ( (200.77 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05793632 Completed
Delirium
Ain Shams University
 March 1 2023 Phase 2
NCT05303935 Completed
Sleep Apnea Obstructive
Flinders University
 May 25 2022 Phase 2
NCT05374356 Unknown status
Post-Operative Confusion
University of Manitoba
 May 2022 Not Applicable
NCT04229875 Recruiting
Bipolar Disorder
Mental Health Services in the Capital Region Denmark|Maria Faurholt-Jepsen MD DMSc|The Mental Health Services in the Capital Region of Denmark
 January 13 2020 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map